
ARE Stock Forecast & Price Target
ARE Analyst Ratings
Bulls say
Alexandria Real Estate Equities Inc. demonstrates a positive outlook due to its strong market presence in vital life science sectors across North America and Canada, which is supported by an expected increase in tenant growth and profitability. The company's ongoing progress in advancing its development pipeline, complemented by a significant $10.8 billion backlog of construction projects, positions it well for future revenue growth. Additionally, the anticipated improvement in public sector demand, coupled with the potential recovery in private sector funding for biotech, further enhances the prospects for sustained demand for purpose-built space in key life science markets.
Bears say
Alexandria Real Estate Equities Inc. is facing a negative outlook due to several concerning fundamental financial metrics, including a year-over-year decline in operating results and a projected decrease in occupancy rates through 2026. The company's financial forecasts have been adjusted downwards, reflecting expectations of higher tenant move-outs and delays in asset sales, which are anticipated to lead to significant drops in core earnings of 28.3% in 2026 and 6.8% in 2027. Additionally, challenges such as oversupply in their markets, the capping of reimbursements for research grants, and potential delays in drug approvals due to government shutdowns further exacerbate the negative financial trajectory.
This aggregate rating is based on analysts' research of Alexandria Real Estate Equities and is not a guaranteed prediction by Public.com or investment advice.
ARE Analyst Forecast & Price Prediction
Start investing in ARE
Order type
Buy in
Order amount
Est. shares
0 shares